Tuesday, 19 August 2014
As effective Biosimilar Monoclonal Antibody approved
A biosimilar medication called CT-P13 was accepted by the European Medicines Agency to enhance symptoms of ankylosing spondylitis (AS) — including ailment movement, incapacity, and mobility with a drug named infliximab, otherwise called Remicade.
As per a study introduced at the European League Against Rheumatism Annual Congress, CT-P13 is the world's first biosimilar monoclonal immune response to get support and gives a less expensive, more financially savvy alternative for patients with AS. Biosimilars are generic versions of biologic medication.
By demonstrating comparable efficacy and safety, the results of our clinical trials should give physicians confidence in using CT-P13 as an alternative treatment option in AS patients,” Park said. “This is good news for patients who may previously have had limited access to costly antibody biopharmaceuticals.”
“Regulated introduction of biosimilars into the market has been forecasted to increase access to much needed biologic medicines and reduce costs,” the report stated. "The biologic medicines market is expected to grow to $190-200 billion by 2015, with biosimilars a small but growing proportion at $2-2.5 billion.”
One big challenge in front of the approved Biosimilars is not only its similar properties to those traditional medicines that it acts as an alternative, but also being highly effective and safe to be used.
There is a latest report on global biosimilar market, which forecasts the market to reach $35 billion by 2020. Biosimilars are definitely better alternatives to biologics.